MuLV packaging systems as models for estimating/measuring retrovirus recombination frequency

Area of Science:

• Retroviral research
• Gene therapy vectorology
• Molecular virology

Background:

• Retrovirus vectors can interact with endogenous retroviruses in packaging and target cells, potentially forming recombinant viruses.
• Assessing contamination of retroviral vectors with endogenous viral sequences is critical for gene therapy safety.

Purpose of the Study:

• To investigate the incorporation of endogenous retrovirus transcripts into murine leukemia virus (MLV) vector particles from human and murine packaging cell lines.
• To determine if vector genomes are packaged into human endogenous retrovirus (HERV) particles.

Main Methods:

• Sensitive reverse transcription-polymerase chain reaction (RT-PCR) assays were employed.
• Analysis of retroviral particles produced by murine AM12 and human FLY packaging cell lines.
• Quantification of endogenous retrovirus sequences and vector genomes within packaged particles.

Main Results:

• Murine packaging cells (AM12) packaged VL30 endogenous retrovirus sequences into MLV vector particles.
• Human packaging cells (FLY) showed minimal to no detectable HERV transcripts in MLV vector particles.
• MLV vector transcripts were detected at a very low level in human FLY virions, and HERV-K particles did not package MLV-based vectors.

Conclusions:

• Human packaging cell lines produce retrovirus particles with significantly less contamination from endogenous viral sequences compared to murine packaging cells.
• This suggests human packaging cells offer a safer platform for retroviral vector production in gene therapy.
• Findings highlight the importance of cell line choice in minimizing risks associated with retroviral vector contamination.